HYTANBIO · SPECIALIST DEVELOPMENT

Peptide & specialist oral film development.

Explore a clearly defined brief for peptide oral films, glutathione and NAD+ concepts. Ingredient feasibility, pharmaceutical assessment and laboratory research each follow a different development path.

Ingredient concepts Pharmaceutical assessment

Peptide oral-film research and development concept 1

A defined starting point

Ten references. A clear scope for each.

This directory records the supplied ingredient brief. Amounts are customer-stated reference targets only; none is a verified finished-film content or a consumer dose. Film appearance is formulation-specific, and the images illustrate development concepts rather than tested products.

Ingredient feasibility

Glutathione and NAD+ concepts.

Explore ingredient compatibility and the practical limits of a thin-film format. A commercial project can proceed only after the exact material, proposed specification and destination-market pathway are accepted.

Ingredient feasibility review

Glutathione

A tripeptide ingredient concept already represented in our oral-film portfolio. A standalone glutathione brief and a glutathione / vitamin C combination are separate formulation decisions.

Customer-stated reference amount: 100 mg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

Review ingredient grade, identity, taste, usable film capacity and finished-film stability before agreeing a specification. A 100 mg request may need a revised film size, format or loading after assessment.

The cited food GRAS notice covers specified intended uses. It does not establish approval of a HYTANBIO oral film or a universal supplement authorization.

Explore the existing glutathione film concept ↗

NAD+ oral-film development concept illustration

Coenzyme feasibility review

NAD+

Nicotinamide adenine dinucleotide is a nucleotide coenzyme. It is included here as a specialist ingredient concept rather than classified as a peptide.

Customer-stated reference amount: 100 mg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

Confirm the exact ingredient form and destination-market status, then assess identity, stability, sensory characteristics and whether the requested amount is practical in a thin-film format.

No longevity, cellular-rejuvenation or absorption benefit is established by this development brief. The proposed loading and any commercial pathway remain unvalidated.

Pharmaceutical assessment

A sponsor-led development pathway.

Semaglutide, tirzepatide and bremelanotide are assessed as pharmaceutical topics, not routine supplement private-label products. No approved HYTANBIO oral-film version, dosage-form equivalence or human-use sample availability is claimed.

Qualified pharmaceutical assessment

Semaglutide

A prescription-drug active requiring a sponsor-led pharmaceutical pathway. Existing semaglutide medicines include authorized tablets and injections; their evidence cannot simply be transferred to a new film.

Customer-stated reference amount: 2 mg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

Review sponsor qualifications, active identity, dosage-form rationale, analytical requirements and the necessary pharmaceutical development and authorization pathway before accepting any scope.

This is not an approved semaglutide oral film, a generic equivalent, or a consumer supplement. No human-use samples or treatment instructions are offered on this page.

Qualified pharmaceutical assessment

Tirzepatide

A prescription-drug active presented only as a pharmaceutical assessment topic. The cited tirzepatide product label describes a subcutaneous injection, not an oral film.

Customer-stated reference amount: 2 mg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

A qualified sponsor must establish the lawful project scope and dosage-form development rationale. Material characterization, finished-film testing and a route-specific evidence plan require separate review.

Injection approvals do not authorize a HYTANBIO oral film. The customer-stated amount is not an equivalent dose, treatment recommendation or confirmed manufacturing specification.

Qualified pharmaceutical assessment

PT-141 / Bremelanotide

PT-141 is commonly used to refer to bremelanotide. The cited approved medicine is a prescription subcutaneous injection; an oral-film brief is a distinct development proposition.

Customer-stated reference amount: 2 mg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

Confirm active identity and sponsor authorization, then determine whether a pharmaceutical assessment can proceed. An agreed evidence plan must address the proposed dosage form and intended market.

No sexual-performance claim, therapeutic equivalence or approved oral-film status is asserted. This directory provides no consumer dosing or administration advice.

Laboratory reference directory

Research information with a defined boundary.

The following entries are restricted to laboratory reference and nonclinical feasibility discussion. They are not consumer oral films and are not offered for human or animal use. No therapeutic benefit or finished-product approval is claimed.

Laboratory reference only

BPC-157

A research-peptide reference for initial identity and evidence review. FDA identifies limited safety information and potential immunogenicity concerns for compounded BPC-157.

Customer-stated reference amount: 500 mcg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

Research discussion is limited to material identity, documentation and nonclinical feasibility questions. A requested film amount does not establish a suitable formulation or human-use pathway.

FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL USE. No finished consumer film, recovery claim or human-use sampling is offered.

Laboratory reference only

CJC-1295

A research reference requiring exact identity confirmation. The name alone does not resolve DAC-related identity differences; FDA also records significant safety concerns for compounded CJC-1295.

Customer-stated reference amount: 150 mcg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

Establish the precise material identity and supporting analytical documentation before considering any nonclinical research scope. The table entry is not a verified oral-film specification.

FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL USE. No growth-hormone, anti-aging or therapeutic benefit is claimed.

Laboratory reference only

GHK-Cu

A copper-peptide ingredient research topic. Experience with cosmetic products or another administration route does not establish the safety or authorization of an ingestible film.

Customer-stated reference amount: 3 mg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

Identity, copper content, material compatibility and appropriate nonclinical documentation are initial review topics. FDA’s cited GHK-Cu concern addresses injectable routes; it is not evidence validating an oral route.

FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL USE. No cosmetic-to-oral safety transfer, skin benefit or approved ingestible product is asserted.

Laboratory reference only

TB-500

A research name that requires exact sequence and identity clarification. A TB-500 trade description should not be assumed to identify full-length thymosin beta-4 or a particular fragment.

Customer-stated reference amount: 500 mcg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

Resolve identity and supporting documentation before a nonclinical feasibility discussion. FDA’s discussion of thymosin beta-4 fragments highlights limited human-exposure information, not an oral-film authorization.

FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL USE. No tissue-repair, injury-recovery or consumer-use film is offered.

Investigational reference only

Retatrutide

An investigational compound recorded for reference review only. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under US federal law.

Customer-stated reference amount: 2 mg

Unvalidated development reference. Not a recommended dose or confirmed film content.

Review focus

The supplied table is retained as an unverified reference brief. This listing does not offer compounded retatrutide, a consumer film, or a human-use sample. Any lawful institutional research would require its own authorization.

FOR LABORATORY REFERENCE ONLY. NOT FOR HUMAN OR ANIMAL USE. A research label does not permit consumer drug marketing or override applicable restrictions.

Evidence before specification

What a feasibility review must resolve.

Identity & intended use

Confirm the precise ingredient, documentation, intended classification, market and qualified project sponsor. A familiar compound name is not a complete specification.

Film suitability & quality

Assess whether a thin-film format is justified and whether identity, content uniformity, stability and packaging can be demonstrated. No fixed loading or absorption improvement is assumed.

Authorized project scope

Agree the lawful scope, evidence requirements and acceptance criteria before a project is accepted. OEM, ODM, CRO or CDMO support depends on the compound and the authorized arrangement.

Explore development capabilities Email a qualified project brief

Development questions

Peptide oral-film project FAQ.

Are these ten commercially available oral-film products?

No. This directory separates ingredient feasibility concepts, qualified pharmaceutical assessment topics and laboratory-only references. Neither the customer brief nor the illustrations establish validated manufacturing, safety, efficacy, stock availability or regulatory authorization.

What do the stated amounts mean?

They reproduce customer-stated amounts for initial review only. They are not recommended doses, measured contents, approved strengths or validated per-film specifications. A request may be changed or declined after technical and market review.

Is NAD+ a peptide?

No. NAD+ is a nucleotide coenzyme. Glutathione is a tripeptide. They appear together here because both were included in the specialist ingredient brief, not because every entry belongs to the same chemical class.

Can an approved injection or tablet be converted into an equivalent film?

Equivalence cannot be assumed. A different dosage form requires its own formulation evidence, quality controls, route-specific assessment and applicable authorization. Dissolving in the mouth does not prove systemic absorption or bioavailability.

What information is needed for a legitimate development inquiry?

Provide the exact ingredient identity, target market, intended product classification, qualified sponsor details where applicable, requested specification and available evidence. Do not send patient information. Research references are not offered for human-use sampling.

Technical and regulatory references.

Reviewed October 8, 2026. These sources describe chemical identity, selected safety concerns or specific authorized products; they do not certify HYTANBIO film concepts. Market status must be checked again for each project.